A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.10, 2001-01, pp. : 1051-1064

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Etanercept - the low-cost route to relief in rheumatoid arthritis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 294, 2001-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Etanercept - the low-cost route to relief in rheumatoid arthritis

Inpharma, Vol. 1, Iss. 1270, 2001-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK

By Barbieri Marco

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 607-618

Adis International

Access to resources Recommend Favorite

TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept

By Mikuls T.R. Moreland L.W.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 75-84

Informa Healthcare

Access to resources Recommend Favorite

Etanercept of value in rheumatoid arthritis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 529, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite